The discovery and evolution of leukemia understanding begins in 1845, when two physicians working independently — John Hughes Bennett in Edinburgh and Rudolph Virchow in Berlin — both described patients whose blood was thick with an abnormal excess of white blood cells. Virchow coined the term “leukämie” from the Greek words for “white” (leukos) and “blood” (haima). That single observation launched nearly two centuries of scientific progress that has transformed leukemia from a universally fatal diagnosis into a disease with cure rates exceeding 90% for some subtypes.
What’s remarkable about this history isn’t just the initial discovery — it’s the pace of change. In the 1960s, childhood acute lymphoblastic leukemia (ALL) killed more than 90% of patients. Today, the 5-year survival rate for pediatric ALL is approximately 90%. That kind of reversal doesn’t happen by accident. It’s the result of dozens of pivotal breakthroughs stacked on top of each other, each one building on the last.
The Key Milestones: A Timeline of Leukemia Discovery
| Year | Milestone | Why It Mattered |
|---|---|---|
| 1845 | Bennett and Virchow describe leukemia | First recognition of leukemia as a distinct disease entity |
| 1847 | Virchow coins the term “leukämie” | Gave the disease a formal name, replacing vague descriptions like “suppuration of the blood” |
| 1868 | Ernst Neumann links leukemia to bone marrow | Identified the bone marrow as the origin of blood cell production — and leukemia |
| 1877 | Paul Ehrlich develops blood cell staining | Allowed physicians to distinguish different white blood cell types for the first time |
| 1913 | Leukemia classified into four main types | Acute vs. chronic, lymphocytic vs. myeloid — a framework still used today |
| 1947 | Sidney Farber uses aminopterin in childhood ALL | First chemotherapy drug to induce temporary remissions in leukemia |
| 1956 | First successful bone marrow transplant (E. Donnall Thomas) | Opened the door to curative hematopoietic stem cell transplantation |
| 1960 | Discovery of the Philadelphia chromosome | First chromosomal abnormality linked to cancer — revolutionized CML understanding |
| 2001 | FDA approves imatinib (Gleevec) for CML | Turned CML from a death sentence into a manageable chronic disease; 10-year survival jumped to ~85% |
| 2017 | FDA approves first CAR-T cell therapy (tisagenlecleucel) | Engineered a patient’s own immune cells to hunt leukemia — a true paradigm shift |
The 1800s: From “White Blood” to a Named Disease
Before 1845, patients who died with massively swollen spleens and blood that appeared milky-white on autopsy were medical curiosities, not diagnostic categories. Bennett initially thought he was observing pus in the blood from an undetected infection. Virchow disagreed — he argued the white cells themselves were the problem, not a secondary infection.
Virchow turned out to be right, and his insistence on cellular pathology — the idea that disease originates in cells rather than in mysterious “humors” — helped reshape all of medicine, not just hematology. By 1868, Ernst Neumann had traced the origin of these abnormal white cells to the bone marrow, establishing the fundamental connection between marrow dysfunction and leukemia that still defines the disease today.
Paul Ehrlich’s development of aniline dye staining techniques in 1877 was another quiet revolution. For the first time, physicians could look at a blood smear under a microscope and differentiate neutrophils from lymphocytes from monocytes. Without this technology, classifying leukemia into meaningful subtypes would have been impossible.
The Early 1900s: Classification Takes Shape
By 1913, researchers had organized leukemia into the four broad categories we still recognize:
- Acute Lymphoblastic Leukemia (ALL) — rapidly progressing, most common in children
- Acute Myeloid Leukemia (AML) — rapidly progressing, more common in adults over 65
- Chronic Lymphocytic Leukemia (CLL) — slow-growing, median diagnosis age around 70
- Chronic Myeloid Leukemia (CML) — slow-growing, linked to the Philadelphia chromosome
This classification was critical because it meant doctors could stop treating “leukemia” as one disease and start tailoring approaches to each subtype. The acute forms progress over days to weeks if untreated; the chronic forms can simmer for years before requiring intervention. Lumping them together had been costing lives.
The Chemotherapy Era: Sidney Farber Changes Everything
In 1947, Sidney Farber — a pathologist at Boston Children’s Hospital — administered aminopterin, a folic acid antagonist, to children dying of ALL. The results were temporary but astonishing: some children achieved complete remission. Before Farber, every single child diagnosed with ALL died. His work proved that chemical agents could push leukemia into retreat, even if they couldn’t yet finish the job.
Throughout the 1950s and 1960s, researchers discovered that combining multiple chemotherapy agents worked far better than any single drug. The concept of combination chemotherapy — attacking cancer through several mechanisms simultaneously — became the backbone of leukemia treatment and remains so today.
E. Donnall Thomas performed the first successful bone marrow transplant in 1956, eventually earning the Nobel Prize in 1990. This procedure gave doctors a way to obliterate a patient’s diseased marrow with high-dose chemotherapy and radiation, then replace it with healthy donor cells. It was brutal, risky, and for many patients, the only chance at cure.
The Genetic Revolution: Philadelphia Chromosome to CAR-T
The 1960 discovery of the Philadelphia chromosome — a translocation between chromosomes 9 and 22 that produces the BCR-ABL fusion protein — was a turning point not just for leukemia, but for all of oncology. It was the first time a specific genetic abnormality had been directly linked to a specific cancer.
It took four decades to translate that discovery into a drug. In 2001, the FDA approved imatinib (Gleevec), a tyrosine kinase inhibitor that specifically blocks the BCR-ABL protein. The results were staggering: CML went from a disease with a median survival of 3–5 years to one where most patients live a near-normal lifespan. The 10-year overall survival rate with imatinib therapy is approximately 83–85%.
More recently, research into epigenetic dysfunctions and signaling pathways — including those driven by mutations in CSF3R, FLT3, and IDH1/2 — has produced a new generation of targeted therapies. Drugs like midostaurin, enasidenib, and venetoclax are giving patients with previously treatment-resistant subtypes meaningful options.
The 2017 FDA approval of CAR-T cell therapy (chimeric antigen receptor T-cell therapy) may ultimately prove to be the biggest leap since chemotherapy itself. This approach re-engineers a patient’s own T-cells to recognize and destroy leukemia cells. In clinical trials for relapsed/refractory pediatric ALL, CAR-T therapy achieved complete remission rates of approximately 81%.
Where We Stand Now: Survival Rates by Leukemia Type
| Leukemia Type | 5-Year Survival Rate (Approximate) | Most Common Age Group |
|---|---|---|
| ALL (children) | ~90% | Ages 2–5 |
| ALL (adults) | ~40% | Over 50 (second peak) |
| AML | ~30% overall; ~65–70% in younger adults | Over 65 |
| CLL | ~87% | Over 70 |
| CML | ~70% (pre-imatinib: ~30%) | Ages 55–65 |
These numbers, compared to the near-zero survival rates of the mid-20th century, represent one of the most dramatic turnarounds in the history of medicine.
Frequently Asked Questions
Who actually discovered leukemia first — Bennett or Virchow?
Both published their findings in 1845, and the priority dispute has never been fully resolved. Bennett published first (in October), but Virchow (publishing in November) provided the more accurate interpretation — that the white cells themselves were pathological, not a sign of infection. Most historians credit Virchow with the conceptual breakthrough, even if Bennett technically published weeks earlier.
Why is leukemia classified into so many subtypes now?
The WHO classification system now recognizes over 30 distinct subtypes of leukemia based on cell lineage, genetic mutations, and molecular markers. This matters because different subtypes respond to entirely different treatments. A drug that works brilliantly for CML (like imatinib) does nothing for AML. Precise classification is the foundation of effective treatment.
Has the incidence of leukemia increased over time?
It’s complicated. Reported cases have increased, largely because diagnostic tools are far more sensitive than they were 50 or 100 years ago. Age-adjusted incidence rates in the U.S. have remained relatively stable at around 13–15 per 100,000 people per year. What has clearly improved is detection — we catch cases now that would have been missed or misdiagnosed in earlier decades.
What was the first chemotherapy drug ever used for leukemia?
Aminopterin, a folic acid antagonist, administered by Sidney Farber in 1947 to children with ALL. Its successor, methotrexate, is still widely used in leukemia treatment protocols today — more than 75 years later.
Is leukemia considered curable now?
For some subtypes, yes. Childhood ALL has cure rates around 90%. Many CML patients on tyrosine kinase inhibitors achieve deep molecular remissions and may eventually discontinue treatment. AML in younger adults is curable in a significant percentage of cases with intensive chemotherapy and/or stem cell transplant. CLL, while often very manageable, is still generally considered incurable — though many patients live decades with the disease.
Key Takeaways
- Leukemia was first described in 1845 by Bennett and Virchow, making it one of the earliest cancers to be formally identified.
- The discovery and evolution of leukemia understanding has progressed through distinct eras: morphologic description (1800s), classification (early 1900s), chemotherapy (1940s–1970s), genetic understanding (1960s–2000s), and targeted/immune therapy (2000s–present).
- Survival rates for several leukemia subtypes have improved dramatically — childhood ALL went from 0% to ~90% survival in about 70 years.
- Imatinib (Gleevec) for CML remains one of the greatest success stories in all of oncology, transforming a fatal disease into a chronic, manageable condition.
- CAR-T cell therapy and new targeted agents continue to push survival rates upward, particularly for relapsed and refractory disease.
If you’re experiencing unexplained fatigue, recurrent infections, easy bruising, or persistent fevers, ask your doctor for a complete blood count (CBC) with differential. This simple, inexpensive blood test is the first step in detecting leukemia and dozens of other blood disorders. Early detection remains one of the most powerful tools we have — and it starts with paying attention to symptoms that don’t resolve on their own.
